ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at the Proactive London studio after confirming to the market that.
Phase 2/3 adaptive clinical trial of P140 in Lupus to commence following FDA meeting 19th June 2023 - 9:43 am ImmuPharma PLC , the specialist drug discovery and development. | June 19, 2023
ImmuPharma PLC - London-based drug discovery and development company - Will start phases two and three of the clinical trial for Lupuzor in the seocnd half of 2023, following talks with the US Food. | June 19, 2023
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) is set to initiate a Phase 2/3 adaptive clinical trial for its P140 (Lupuzor) drug in systemic lupus erythematosus.